SK Telecom and NVIDIA have formed a new alliance to expand AI infrastructure in Korea, deploying NVIDIA’s DSX AI Factory Architecture. The collaboration centers on accelerating AI startups, robotics, and industrial physical AI, showcasing Korea’s determined push toward tech-based innovation.

In a bold move to meet the soaring global demand for advanced AI solutions, NAVER is joining forces with NVIDIA to build AI factories at gigawatt scale. By tapping into NVIDIA’s DSX technology, the partnership aims to usher in next-generation applications for AI agents and physical systems.

Omnix Medical has begun enrolling patients in a Phase II trial of OMN6, a new antimicrobial compound designed to physically disrupt pathogenic bacteria. This breakthrough approach underscores the potential for a novel treatment pathway that could reshape the landscape of antibacterial therapies.

WIN EURASIA 2026, recognized as one of the leading industrial trade fairs in the Eurasian region, will converge on Istanbul to spotlight the latest advancements in automation. This eagerly awaited event aims to shape new pathways for manufacturing and demonstrate how cutting-edge technologies can drive industry-wide progress.

Savara (Nasdaq: SVRA) has released encouraging long-term Phase 3 data suggesting that patients receiving molgramostim for an autoimmune pulmonary condition continue to see improved lung function and respiratory health. Announced in Langhorne, Pennsylvania, the results spotlight a potential breakthrough for individuals affected by persistent breathing challenges.

Changingtek Robotics has introduced Uhand, a high-precision tactile data collection hand launched from Suzhou, China. Engineered to capture synchronized, multi-dimensional, and multimodal data, Uhand aims to support advanced robotics research and precision manipulation tasks. Its global rollout marks an important step forward in the development of embodied intelligent robots.

A growing tide of clinical research is transforming synovial sarcoma treatment prospects. According to DelveInsight Business Research LLP, over 15 pharmaceutical firms are developing more than 20 new therapies, reflecting a heightened commitment to tackling this rare cancer.

A new report highlights more than 75 drugs under consideration for Duchenne muscular dystrophy, promising significant progress in patient care. The analysis explores clinical strategies, upcoming therapies, and commercial prospects, signaling a major shift in the DMD landscape.

Two of Climb Bio’s most promising therapies—CLYM116 and budoprutug—will be in the spotlight at the European Renal Association Congress 2026. The company is sharing early safety data and a Phase 2 trial update in Glasgow, Scotland, detailing its mission to advance treatment options for immune-mediated kidney diseases.

Absci stands at the forefront of an emerging AI-biotech revolution, aiming to reinvent how new drugs are discovered. Though the investment case is undeniably speculative, many believe it could redefine pharmaceutical innovation by 2036.

Royal Caribbean is introducing robots to its Icon Class ships, ushering in a fresh approach to maritime innovation. By integrating collaborative robots, or “cobots,” the cruise line aims to streamline and enhance various onboard tasks, including housekeeping.

Groundbreaking news from Immusoft reveals the treatment of the world’s first patient with a B cell-based therapy. With support from the FDA and ARM, the company showcases a next-generation approach focusing on scalability and re-dosability.

Waymo will roll out a pilot program for its driverless taxis on London’s streets in April 2026. The initiative aims to explore how self-driving vehicles function in this bustling metropolis, potentially shifting the city’s transportation landscape in the near future.

Aldeyra Therapeutics has been hit by a securities fraud lawsuit alleging that it covered up inconsistencies in clinical trial data for its eye treatment candidate, reproxalap. Investors who purchased shares during the specified period and experienced losses may now seek to lead the class action.

Neutrolis, Inc. has released positive results from the Phase 1a portion of its LIBERATE-I trial, spotlighting NTR-1011’s potential in dismantling harmful Neutrophil Extracellular Traps (NETs). This first-in-class DNASE1L3 fusion protein aims to address chronic inflammatory pathways without compromising the immune system.

As technological advances blur the lines once described in science fiction, even nature’s tiniest marvels—the hummingbirds—are touched by innovation. This story explores the intersection between feathered wildlife and our ever-evolving gadgets, raising anew the question of how far technology might go.

LG Innotek has signed a partnership agreement with Applied Intuition, an autonomous driving software firm. The collaboration aims to drive LG Innotek’s entry into the emerging Physical AI market, signaling a fresh push for innovation in technology.

Applied Intuition and LG Innotek have joined forces to streamline the path toward autonomous vehicles. This partnership combines advanced camera sensors, real-world testing, and simulation to help original equipment manufacturers (OEMs) achieve production-ready autonomy more quickly.

Amazon’s preview Spring Sale is offering discounts as high as 45% off on certain robot vacuum models. A self-described robot vacuum tester highlights seven standout options—and warns about which products might not be worth your money.

RevnaBio’s newly secured triple accreditation across ISO 15189, ISO 20387, and ISO/IEC 17043 marks a significant step in advancing clinical research in Africa. This milestone is poised to strengthen diagnostic quality and expand precision medicine on the continent.

WIRobotics has secured its place in the second cohort of the Physical AI Fellowship, a virtual program that supports promising startups through resources from AWS Startups, NVIDIA Inception, and MassRobotics. Announced on March 12, 2026, this milestone underscores WIRobotics’ expanding role in AI-driven robotics.